search
Back to results

Pelvic Health Electrically Evoked Recording (PEER) 2 Study (PEER 2)

Primary Purpose

Overactive Bladder, Fecal Incontinence, Urinary Retention

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sacral Neuromodulation
Sponsored by
MedtronicNeuro
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Overactive Bladder

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Overactive Bladder Criteria Inclusion Criteria

  1. 18 years of age or older
  2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation
  3. Willing and able to provide signed and dated informed consent
  4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  5. Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation
  6. For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary.
  7. For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary.

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Non-Obstructive Urinary Retention Inclusion Criteria

  1. 18 years of age or older
  2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation
  3. Willing and able to provide signed and dated informed consent
  4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  5. Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation
  6. Have a diagnosis of non-obstructive urinary retention as demonstrated by a urinary voiding diary with a minimum of 5 clean intermittent self-catheterizations in a 7-day period; and chronic non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions.

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Fecal Incontinence Inclusion Criteria

  1. 18 years of age or older
  2. Candidate for or undergoing Medtronic InterStim lead implant labeled indication* requiring an advanced evaluation
  3. Willing and able to provide signed and dated informed consent
  4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  5. Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation
  6. Have a diagnosis of fecal incontinence as demonstrated by a bowel diary as greater than or equal to 2 incontinent episodes of more than staining (i.e., either slight, moderate, or severe soiling) per week

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Exclusion Criteria:

Overactive Bladder Criteria Exclusion Criteria

  1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  2. Implanted with a neurostimulator, pacemaker or defibrillator
  3. Pelvic floor muscle dysfunction due to surgical intervention or injury
  4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  5. History of diabetes unless the diabetes is well-controlled through diet and/or medications
  6. Have symptomatic urinary tract infection (UTI)
  7. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component
  8. Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study
  9. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  10. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  11. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  12. Women who are pregnant or planning to become pregnant
  13. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
  14. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Non-Obstructive Urinary Retention Exclusion Criteria

  1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  2. Implanted with a neurostimulator, pacemaker or defibrillator
  3. Pelvic floor muscle dysfunction due to surgical intervention or injury
  4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  5. History of diabetes unless the diabetes is well-controlled through diet and/or medications
  6. Have symptomatic urinary tract infection (UTI)
  7. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  8. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  9. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  10. Women who are pregnant or planning to become pregnant
  11. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
  12. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Fecal Incontinence Exclusion Criteria

  1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  2. Implanted with a neurostimulator, pacemaker or defibrillator
  3. Pelvic floor muscle dysfunction due to surgical intervention or injury
  4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  5. Have uncorrected high grade internal rectal prolapse
  6. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  7. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  8. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  9. Women who are pregnant or planning to become pregnant
  10. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Sites / Locations

  • Indiana University Health Methodist Research InstituteRecruiting
  • LSUHSC Department of Urology
  • Ochsner Clinic FoundationRecruiting
  • Mayo Clinic Urology/Urogynecology DepartmentRecruiting
  • University Hospitals Cleveland Medical CenterRecruiting
  • OhioHealth Physician's Group UrologyRecruiting
  • DHR Health Institute for Research and DevelopmentRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Pelvic health Electrically Evoked Recording (PEER) 2 Study

Arm Description

Collect physiological signals

Outcomes

Primary Outcome Measures

Number of subjects with physiological signals collected at each timepoint
The proportion of subjects with evaluable signals will be summarized at each timepoint

Secondary Outcome Measures

Full Information

First Posted
December 20, 2021
Last Updated
April 25, 2023
Sponsor
MedtronicNeuro
search

1. Study Identification

Unique Protocol Identification Number
NCT05200923
Brief Title
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
Acronym
PEER 2
Official Title
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 18, 2022 (Actual)
Primary Completion Date
December 18, 2026 (Anticipated)
Study Completion Date
December 18, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MedtronicNeuro

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To collect physiological signals at several timepoints during the therapy evaluation period.
Detailed Description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this non-applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overactive Bladder, Fecal Incontinence, Urinary Retention

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Pelvic health Electrically Evoked Recording (PEER) 2 Study
Arm Type
Experimental
Arm Description
Collect physiological signals
Intervention Type
Device
Intervention Name(s)
Sacral Neuromodulation
Intervention Description
Sacral neuromodulation delivers electrical stimulation to a sacral nerve
Primary Outcome Measure Information:
Title
Number of subjects with physiological signals collected at each timepoint
Description
The proportion of subjects with evaluable signals will be summarized at each timepoint
Time Frame
1 day to 7 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Overactive Bladder Criteria Inclusion Criteria 18 years of age or older Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation Willing and able to provide signed and dated informed consent Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary. For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary. Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Non-Obstructive Urinary Retention Inclusion Criteria 18 years of age or older Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation Willing and able to provide signed and dated informed consent Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation Have a diagnosis of non-obstructive urinary retention as demonstrated by a urinary voiding diary with a minimum of 5 clean intermittent self-catheterizations in a 7-day period; and chronic non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions. Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Fecal Incontinence Inclusion Criteria 18 years of age or older Candidate for or undergoing Medtronic InterStim lead implant labeled indication* requiring an advanced evaluation Willing and able to provide signed and dated informed consent Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation Have a diagnosis of fecal incontinence as demonstrated by a bowel diary as greater than or equal to 2 incontinent episodes of more than staining (i.e., either slight, moderate, or severe soiling) per week Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Exclusion Criteria: Overactive Bladder Criteria Exclusion Criteria Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) Implanted with a neurostimulator, pacemaker or defibrillator Pelvic floor muscle dysfunction due to surgical intervention or injury Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) History of diabetes unless the diabetes is well-controlled through diet and/or medications Have symptomatic urinary tract infection (UTI) Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study Treatment of symptoms with tibial neuromodulation therapy in the last 3 months Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy Women who are pregnant or planning to become pregnant Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture) Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Non-Obstructive Urinary Retention Exclusion Criteria Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) Implanted with a neurostimulator, pacemaker or defibrillator Pelvic floor muscle dysfunction due to surgical intervention or injury Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) History of diabetes unless the diabetes is well-controlled through diet and/or medications Have symptomatic urinary tract infection (UTI) Treatment of symptoms with tibial neuromodulation therapy in the last 3 months Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy Women who are pregnant or planning to become pregnant Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture) Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Fecal Incontinence Exclusion Criteria Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) Implanted with a neurostimulator, pacemaker or defibrillator Pelvic floor muscle dysfunction due to surgical intervention or injury Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) Have uncorrected high grade internal rectal prolapse Treatment of symptoms with tibial neuromodulation therapy in the last 3 months Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy Women who are pregnant or planning to become pregnant Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nichole Carlson
Phone
7635262757
Email
nichole.carlson@medtronic.com
First Name & Middle Initial & Last Name or Official Title & Degree
Anne Miller
Phone
7635263583
Email
anne.e.miller@medtronic.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nichole Carlson
Organizational Affiliation
Medtronic Pelvic Health
Official's Role
Study Director
Facility Information:
Facility Name
Indiana University Health Methodist Research Institute
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charles Powell
Phone
317-944-4622
Email
crpowell@iupui.edu
First Name & Middle Initial & Last Name & Degree
Courtney Dhondt
Phone
(317) 274-1791
Email
cgerler@iu.edu
First Name & Middle Initial & Last Name & Degree
Charles Powell
Facility Name
LSUHSC Department of Urology
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Individual Site Status
Withdrawn
Facility Name
Ochsner Clinic Foundation
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70121
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Neeti Galwankar
Phone
504-842-9971
Email
neeti.galwankar@ochsner.org
First Name & Middle Initial & Last Name & Degree
Rachel Graham
Email
rgraham@ochsner.org
First Name & Middle Initial & Last Name & Degree
Colin Goudelocke
Facility Name
Mayo Clinic Urology/Urogynecology Department
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Burnette
Phone
507-422-9146
Email
David.burnette@mayo.edu
First Name & Middle Initial & Last Name & Degree
Brian Linder
Facility Name
University Hospitals Cleveland Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steven Madias
Phone
216-844-1447
Email
steven.madias@uhhospitals.org
First Name & Middle Initial & Last Name & Degree
David Sheyn
First Name & Middle Initial & Last Name & Degree
Adonis Hijaz
Facility Name
OhioHealth Physician's Group Urology
City
Hilliard
State/Province
Ohio
ZIP/Postal Code
43026-2050
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ketul Shah
Phone
614-544-1460
Email
ketul.shah@ohiohealth.com
First Name & Middle Initial & Last Name & Degree
Kevin Miller
Phone
(614) 788-3886
Email
kevin.miller@ohiohealth.com
First Name & Middle Initial & Last Name & Degree
Ketul Shah
Facility Name
DHR Health Institute for Research and Development
City
Edinburg
State/Province
Texas
ZIP/Postal Code
78539
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henry Ruiz
Phone
956-362-8767
Email
henryeruiz@gmail.com
First Name & Middle Initial & Last Name & Degree
Kayllie Lomeli
Phone
(956) 362-2393
Email
k.lomeli@dhr-rgv.com
First Name & Middle Initial & Last Name & Degree
Henry Ruiz
First Name & Middle Initial & Last Name & Degree
Gustavo Villegas
First Name & Middle Initial & Last Name & Degree
Adrienne Casciato

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Pelvic Health Electrically Evoked Recording (PEER) 2 Study

We'll reach out to this number within 24 hrs